Zydus Lifesciences has informed that it enclosed copy of two press releases, both dated March 28, 2023, ‘Zydus receives Final Approval from the USFDA for Levothyroxine Sodium for Injection’ and ‘Zydus receives Final Approval from the USFDA for Doxepin Hydrochloride Capsules’.
The above information is a part of company’s filings submitted to BSE.